Department of Pharmaceutics, Rajiv Academy for Pharmacy, Chattikkara, Mathura, India.
Drug Dev Ind Pharm. 2013 May;39(5):780-90. doi: 10.3109/03639045.2012.707203. Epub 2012 Aug 9.
The objective of the present research was to develop a novel pH triggered nanoemulsified in-situ gel (NE-ISG) for ophthalmic delivery of fluconazole (FLZ) to enhance the permeation and residence time of the formulation, by overcoming the limitations associated with protective ocular barriers. Pseudoternary phase diagrams were constructed using capmul MCM (oil phase), tween 80 (surfactant) and transcutol P (cosurfactant) to identify the NE region. Nanoemulsions (NE1-NE6) of FLZ were prepared by spontaneous emulsification method and evaluated for various pharmacotechnical characteristics. NE4 was selected as optimized NE and was dispersed in carbopol 934 solution to form nanoemulsified sols (NE-ISG1 to NE-ISG5) that were expected to convert in to in-situ gels at corneal pH (7.4). The optimized NE-ISG was selected on the basis of gelation ability with a residence time up to or more than 6 h. Ex-vivo transcorneal permeation study displayed significantly higher (p < 0.05) permeation of FLZ from NE-ISG5 (337.67 µg/cm(2)) and NE4 (419.30 µg/cm(2)) than the commercial eye drops (112.92 µg/cm(2)). Hen's egg test-Chorioallantoic membrane (HET-CAM) test with zero score indicated the non-irritant property of developed NE-ISG5. Corneal toxicity study revealed no visual signs of tissue damage. Hence it can be concluded that NE-ISG5 may offer a more intensive treatment of ocular fungal infections due to higher permeation, prolonged precorneal residence time and sustained drug release along with higher in-vitro efficacy, safety and greater patient compliance.
本研究的目的是开发一种新型 pH 触发型纳米乳化原位凝胶(NE-ISG),用于眼部递氟康唑(FLZ),以克服与保护性眼屏障相关的限制,从而增强制剂的渗透和滞留时间。使用 capmul MCM(油相)、吐温 80(表面活性剂)和 transcutol P(助表面活性剂)构建伪三元相图,以确定 NE 区域。通过自发乳化法制备 FLZ 的纳米乳(NE1-NE6),并对其进行各种药剂学特性评价。选择 NE4 作为优化的 NE,并将其分散在 carbopol 934 溶液中,形成纳米乳化溶胶(NE-ISG1 至 NE-ISG5),预计在角膜 pH(7.4)下转化为原位凝胶。根据凝胶形成能力和滞留时间达到或超过 6 小时的情况,选择优化的 NE-ISG。体外角膜渗透研究显示,NE-ISG5(337.67 µg/cm(2))和 NE4(419.30 µg/cm(2))的 FLZ 渗透明显更高(p < 0.05),高于市售滴眼液(112.92 µg/cm(2))。零评分的鸡胚绒毛尿囊膜(HET-CAM)试验表明,所开发的 NE-ISG5 具有非刺激性。角膜毒性研究显示没有组织损伤的视觉迹象。因此,可以得出结论,NE-ISG5 可能由于更高的渗透、更长的预角膜滞留时间和持续的药物释放以及更高的体外功效、安全性和更大的患者依从性,为眼部真菌感染提供更强化的治疗。